Breaking news: F.D.A. delays action on closely watched Alzheimer’s drug

A drug that was expected to be approved soon must instead undergo more regulatory scrutiny.

View in browser|nytimes.com Continue reading the main story March 8, 2024 BREAKING NEWS Mike Segar/Reuters F.D.A. Delays Action on Closely Watched Alzheimer's Drug Eli Lilly's donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug's safety and efficacy. Read more Get more breaking news in your inbox Sign up to receive emails from The New York Times as soon as important news breaks around the world. Get it in your inbox Continue reading the main story ADVERTISEMENT Continue reading the main story Need help? Review our newsletter help page or contact us for assistance. You received this message because you signed up for updates from The New York Times. To stop receiving From The Times, unsubscribe. To opt out of other promotional emails from The Times, including those regarding The Athletic, manage your email settings. To opt out of updates and offers sent from The Athletic, submit a request. Subscribe to The TimesGet The New York Times app Connect with us on: Change Your EmailPrivacy PolicyContact UsCalifornia Notices The New York Times Company. 620 Eighth Avenue New York, NY 10018